I want weight-loss research to tell us more than how much lighter someone became. What changed in their body, and what happened to the strength they need for everyday life?
The STEP 1 body-composition analysis included 140 adults with overweight or obesity; 76% were female. After 68 weeks, those taking semaglutide — the active ingredient in Ozempic and Wegovy — had a 19.3% reduction in fat mass and a 9.7% reduction in lean mass.
How can lean mass fall but its share rise?
Because fat fell by more, lean mass made up a larger proportion of the remaining body weight. That does not mean no lean mass was lost.
The report is a conference abstract from an exploratory DXA scan analysis. Lean mass is not a direct measurement of skeletal-muscle strength, and these were not menopause-specific findings.
For me, the next question is how someone functions as their weight changes. The scales, a scan and everyday strength each tell us something different.